Publication details
Která kombinace duální antiagregace bude u mého pacienta v souvislosti s akutním koronárním syndromem nejlepší? Přehled současných vědeckých poznatků a praktických doporučení
| Title in English | Cardiac function in hypertensive patients with metabolic syndrome and microalbuminuria |
|---|---|
| Authors | |
| Year of publication | 2016 |
| Type | Article in Periodical |
| Magazine / Source | Interní medicína pro praxi |
| MU Faculty or unit | |
| Citation | |
| Field | Cardiovascular diseases incl. cardiosurgery |
| Keywords | dual antiplatelet therapy; P2Y12 inhibitor; acute coronary syndrom |
| Description | Dual antiplatelet therapy (DAT) together with coronary intervention are the cornerstone of the treatment of acute coronary syndrom (ACS). DAT decreases both acute and late ischemic complications but, on contrary, increases the risk of bleeding. The combination of acetylsalicylic acid (ASA) and clopidogrel had been used for a long time. Recently we have been given more potent P2Y12 receptor inhibitors prasugrel and ticagrelor. Current guidelines prefer these drugs in majority of the patients over clopidogrel. There are differencies in farmacology of these drugs and specific contraindications but no head to head randomized clinical trials. Having reviewed the published data, one can postulate that our patients might profit from one drug over another when respecting their comorbidities, type of acute coronary syndrom, clinical manifestation, treatment strategy and intensity. For each individual patient, time of first dose administration of DAT as well as the duration of therapy may vary. In this review, we summarize scientific data available about P2Y12 inhibitors and share our clinical experience with indications, pros and cons of combinations of ASA and novel antiplatelet agents. |